Novavax Inc. Stock
€8.95
Your prediction
Novavax Inc. Stock
Pros and Cons of Novavax Inc. in the next few years
Pros
Cons
Performance of Novavax Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novavax Inc. | -1.280% | 4.274% | 22.259% | 19.040% | 55.084% | 40.527% | -94.725% |
| Heron Therapeutics Inc. | -5.000% | -7.083% | -20.452% | -64.977% | -30.521% | -65.330% | -94.528% |
| Evolus Inc | 0.000% | -8.936% | 18.889% | -63.729% | -21.468% | -45.823% | -56.442% |
| Sangamo Therapeutics Inc. | -5.730% | 2.026% | 1.590% | -62.380% | -5.003% | -84.119% | -96.551% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.General Impression
The financials of Novavax, a Biotechnology & Medical Research company with US symbol NVAX, paint a mixed picture. Over the past few years, the company has reported a significant increase in its revenue and total assets. However, its net income has consistently been in the negative, and it has faced challenges in maintaining a positive net working capital and managing its liabilities.
Detailed Analysis
Comments
News
This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy?
Over the past five years, Novavax (NASDAQ: NVAX), a vaccine maker, lost more than 90% of its market value. Though it succeeded in its goal of launching a coronavirus vaccine, the biotech did so much
Why I Wouldn't Touch Novavax With a 10-Foot Pole
Novavax (NASDAQ: NVAX) was once a leading contender to dominate the coronavirus vaccine market. The company faced several challenges, however, and although it successfully launched its vaccine